Vera Therapeutics, Inc. (VERA)

Vera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-299.62	-152.15	-95.99	-89.06	-32.61
Depreciation & Amortization	0.47	0.11	0.02	-0.85	0.18
Loss (Gain) From Sale of Assets	-	-	-	-	-2.69
Asset Writedown & Restructuring Costs	-	-	-	-	-1
Loss (Gain) From Sale of Investments	-6.98	-8.97	-4.43	0.81	0.89
Stock-Based Compensation	37.93	20.8	11.49	8.89	3.01
Other Operating Activities	4.11	2.87	2.55	5.86	5
Change in Accounts Payable	13.91	-3.45	-0.87	10.61	0.48
Change in Other Net Operating Assets	9.08	6.11	-4.95	-3.86	3.04
Operating Cash Flow	-241.1	-134.68	-92.18	-67.6	-23.71
Capital Expenditures	-0.63	-0.97	-0.06	-0.06	-
Sale of Property, Plant & Equipment	-	-	-	-	0.8
Sale (Purchase) of Intangibles	-	-	-	-	-5
Investment in Securities	195.72	-424.06	-39.37	-70.49	-
Other Investing Activities	-0.8	-	-	-	-
Investing Cash Flow	194.29	-425.03	-39.43	-70.55	-4.2
Long-Term Debt Issued	23.34	-	24.74	19.82	4.92
Total Debt Issued	23.34	-	24.74	19.82	4.92
Net Debt Issued (Repaid)	23.34	-	24.74	19.82	4.92
Issuance of Common Stock	306.98	645.91	116.06	88.21	51.73
Repurchase of Common Stock	-	-0.01	-	-	-
Other Financing Activities	-21.42	-39.23	-7.26	-6.1	-2.77
Financing Cash Flow	308.9	606.67	133.54	101.93	53.88
Net Cash Flow	262.08	46.97	1.93	-36.22	25.97
Free Cash Flow	-241.73	-135.65	-92.24	-67.66	-23.71
Free Cash Flow Per Share	-3.76	-2.45	-2.16	-2.55	-1.76
Cash Interest Paid	6.72	6.65	3.35	0.9	0.02
Levered Free Cash Flow	-139.02	-84.35	-58.02	-42.37	-20.38
Unlevered Free Cash Flow	-134.32	-79.58	-55.66	-41.75	-20.37
Change in Working Capital	22.99	2.66	-5.82	6.75	3.51

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q